FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2020/04/024851 [Registered on: 24/04/2020] Trial Registered Prospectively
Last Modified On: 23/04/2020
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Nutraceutical
Other (Specify) [Herbal mouthwash containing Nutraceuticals]  
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   Herbal mouth wash to minimise radiation induced mucositis in head and neck cancer patients 
Scientific Title of Study   Randomised controlled trial to test the efficacy of herbal mouth wash in managing acute toxicity of radiation in Head & Neck cancer patients 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  DrK Ramadas 
Designation  Professor and Head ,Department of Radiation Oncology ,Regional Cancer Centre,Thiruvananthapuram 
Affiliation  Regional Cancer Centre, Thiruvananthapuram 
Address  Dr.K Ramadas Professor and Head ,Department of Radiation Oncology ,Regional Cancer Centre,Thiruvananthapuram

Thiruvananthapuram
KERALA
PIN 695011
India 
Phone  9447042309  
Fax    
Email  ramdasrcc@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  DrK Ramadas 
Designation  Professor and Head ,Department of Radiation Oncology ,Regional Cancer Centre,Thiruvananthapuram 
Affiliation  Regional Cancer Centre, Thiruvananthapuram 
Address  Dr.K Ramadas Professor and Head ,Department of Radiation Oncology ,Regional Cancer Centre,Thiruvananthapuram


KERALA
PIN 695011
India 
Phone  9447042309  
Fax    
Email  ramdasrcc@gmail.com  
 
Details of Contact Person
Public Query
 
Name  DrK Ramadas 
Designation  Professor and Head ,Department of Radiation Oncology ,Regional Cancer Centre,Thiruvananthapuram 
Affiliation  Regional Cancer Centre, Thiruvananthapuram 
Address  Dr.K Ramadas Professor and Head ,Department of Radiation Oncology ,Regional Cancer Centre,Thiruvananthapuram


KERALA
PIN 695011
India 
Phone  9447042309  
Fax    
Email  ramdasrcc@gmail.com  
 
Source of Monetary or Material Support  
REGIONAL CANCER CENTRE, TRIVANDRUM in collaboration with Rajiv Gandhi Centre For Biotechnology, Thiruvananthapuram and Ceego Labs Pvt Ltd, Chennai  
 
Primary Sponsor  
Name  Regional Cancer Centre Trivandrum 
Address  Regional Cancer Centre, Medical College Campus, Trivandrum, PIN 695011 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
DrK Ramadas  Regional Cancer Centre,Thiruvananthapuram  Dr.K Ramadas Professor and Head Radiation Oncology, Regional Cancer Centre,Thiruvananthapuram
Thiruvananthapuram
KERALA 
9447042309

ramdasrcc@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Human Ethics Committee,Regional Cancer Centre, Thiruvananthapuram  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: C00-C14||Malignant neoplasms of lip, oral cavity and pharynx,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Soda saline mouth wash  Two formulations of herbal mouthwash containing 5 plant ingredients-Emblica officinalis (dried fruit), Terminalia chebula (dried fruit), Terminalia bellerica (dried fruit), Azadiracta indica (leaf & Bark), Glycyrrhiza glabra (root)  
Intervention  Two formulations of herbal mouth wash  3 Arm trial using 2 formulations of herbal mouthwash containing 5 plant ingredients-Emblica officinalis (dried fruit), Terminalia chebula (dried fruit), Terminalia bellerica (dried fruit), Azadiracta indica (leaf & Bark), Glycyrrhiza glabra (root) and third arm using sodasaline mouthwash( control arm) in patients undergoing radical/adjuvant radiotherapy for oral cancer  
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  70.00 Year(s)
Gender  Both 
Details  Patients with oral cancer undergoing radical / adjuvant radiotherapy with or without surgery will be included. 
 
ExclusionCriteria 
Details  Patients who require adjuvant chemoradiation will not be included. 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   An Open list of random numbers 
Blinding/Masking   Outcome Assessor Blinded 
Primary Outcome  
Outcome  TimePoints 
To find out whether the two forms of mouth wash is useful in minimizing side effects of radiation in patients undergoing radiotherapy for oral cancers in terms of oral hygiene, in minimising oral mucositis and in decreasing the severity of analgesic and antibiotic usage.

 
At baseline, Weekly,
at the end of radiotherapy treatment and 6 weeks after the treatment 
 
Secondary Outcome  
Outcome  TimePoints 
degree of xerostomia, intolerance to spicy food and the tumour response.  6 weeks after the completion of treatment 
 
Target Sample Size   Total Sample Size="129"
Sample Size from India="43" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   30/04/2020 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   1. R Kunnambath, D Ravindran, R R Kumar, R.Muwonge, R.M. Pillai. Management of Radiation-Induced Oral Mucositis With a Herbal Mouthwash. Int J Radiat Oncol Biol Phys.2013; 87(Supplement 2): S 143. 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary  

 

Randomised controlled trial to test the efficacy of herbal mouth wash in managing acute toxicity of radiation in Head & Neck cancer patients

Introduction

Oral mucositis is the major dose limiting side effect for patients with oral cancer undergoing radiotherapy.  Mucositis  can interfere with the patient’s ability to maintain adequate intake of food and liquids.  Severe mucositis can lead to treatment interruptions or premature termination of therapy resulting in poor tumour control and survival.  All patients undergoing radiotherapy to oral cavity develop some degree of mucositis

Several agents have been tried to minimize the severity of oral mucositis.  But so far, no method has mentioned has been found to be effective. Regional Cancer Centre, Trivandrum has done a study earlier using an ayurvedic mouth wash containing 5 plant ingredients-Emblica officinalis (dried fruit), Terminalia chebula (dried fruit), Terminalia bellerica (dried fruit), Azadiracta indica (leaf & Bark), Glycyrrhiza glabra (root) in patients undergoing radiotherapy for oral cancer1. One hundred and forty eight patients were randomly assigned to use ayurvedic mouth wash or the standard practice of soda / saline mouthwash. 

 

The ayurvedic mouth wash delayed the onset of oral mucositis during radiotherapy. Oral hygiene was significantly better in patients using ayurvedic mouth wash. Analgesic  and antibiotic requirements were also low in these patients.  There was a significant decrease in the late side effects of radiation to the oral cavity such as dryness of mouth, intolerance to spicy food in the patients who used ayurvedic  mouthwash. Use of this mouth wash did not affect the response to radiotherapy in  these patients.

The major drawback of this mouth wash was the process of preparation of the mouth wash by the patient and also the shelf life.  In order to overcome this RCC in collaboration with RGCB and Ceego Labs Pvt Ltd, Chennai has developed mouth wash using the same ingredients with the same quantity in two forms; one as a ready to use liquid form and another one in a powder form which can be dissolved in water and can be used.

 

Aim    

To find out whether these two forms of mouth wash is useful in minimizing the side effects of radiation in patients undergoing radiotherapy for Head & Neck Cancers

Methodology

            Patients with oral cancer undergoing radical / adjuvant radiotherapy with or without surgery will be randomized into 3 arms after getting informed consent.  Those who require adjuvant chemoradiation will not be included.  However, induction chemotherapy is not an exclusion criteria.  One arm will be using the liquid form of mouthwash 5 ml dissolved in 20 ml of water.  Second one will be using mouth wash prepared by dissolving 30 gm of the powder dissolved in 300 ml of water and the control arm will be using the soda saline mouthwash.  All patients will be advised to rinse the mouth with the mouth wash 4 times daily during the entire course of radiotherapy treatment. 

 

            All these patients will be evaluated weekly. Mucositis grade will be expressed on a 5-point scale using RTOG / ECOG scoring system.  The intensity of pain, dryness of mouth, alteration and taste will be scored on a 10 – point scale using a Visual Analogus Scale (VAS).   The use of analgesics, antibiotics and antifungal and oral hygiene will be recorded in a structured proforma.    Measurements of Weight (Wt) will be done before and after radiotherapy.  All these patients will be reviewed 6 weeks following the treatment to evaluate the degree of xerostomia, intolerance to spicy food and the tumour response.

 

The sample size is calculated based on the previous study.  Assuming 80% power, 5% and error sample size required is 43 in each arm

 

Reference

1.    R Kunnambath, D Ravindran, R R Kumar, R.Muwonge, R.M. Pillai. Management of Radiation-Induced Oral Mucositis With a Herbal Mouthwash. Int J Radiat Oncol Biol Phys.2013; 87(Supplement 2): S 143.

 

 
Close